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Preface
This 2012 update of the 2011 revision of the A Public H ealth Action Plan to Com bat 
Antim icrobial Resistance, provides a listing of projects that the Federal Agencies in the 
Interagency Task Force on Antimicrobial Resistance are pursuing or planning to pursue in an 
effort to respond to the complex and pressing topic of antimicrobial resistance. The past decade 
has seen extraordinary change in the microbiology and epidemiology of antimicrobial-resistant 
microbes and subsequent changes in treatment and patient outcomes. The Task Force is taking 
further strides to ensure that the Action Plan remains current and relevant as the agencies 
continue to look towards the future by taking the following steps:
• Actions, the numbered items that follow each goal, will be reviewed biennially by the Task 
Force beginning in 2013. New actions will be added as needed and existing actions may be 
modified or deleted in response to progress or changes that occur in the future with regard to 
antimicrobial resistance. This will allow the Action Plan to be updated over time and will 
help all Task Force agencies to continue to collaborate most effectively in achieving Action 
Plan goals.
• Implementation steps or projects, the lettered items that follow action items, are being 
revised annually. In this first annual update, new projects have been added, and some 
existing projects have been modified in response to intervening events. Completed projects 
have been moved to an Appendix, and their outcomes will be cross-referenced to the yearly 
progress report for the year during which the project was completed. For example, projects 
completed in 2011 are listed in Appendix A: R etired  P rojects an d  Implementation Steps. The 
outcomes of these projects can be found in the 2011 Progress Towards Implementation of: A 
Public H ealth Action Plan To Com bat Antim icrobial Resistance.
The Task Force and all participating Federal agencies continue to stress the importance of good 
communication with the many stakeholders who share the Task Force’s goals of preventing and 
controlling antimicrobial resistant infections. The Task Force remains committed to continuing 
communication with the public and health professionals, since antimicrobial resistance so 
profoundly affects public health and clinical medicine. Among these efforts is the 2012 annual 
public meeting of the Task Force, scheduled for November 15. Given the public health 
consequences of AR and its ever-changing nature, the Task Force will continue to address the 
issue of antimicrobial resistance in this and future versions of the Action Plan.
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A Public Health Action Plan to Combat Antimicrobial Resistance
Executive Summary
The Interagency Task Force on Antimicrobial Resistance (hereafter referred to as the Task 
Force) was created in 1999 to coordinate the activities of federal agencies in addressing 
antimicrobiala resistance (AR) in recognition of the increasing importance of AR as a public 
health threat. The Task Force is co-chaired by the Centers for Disease Control and Prevention 
(CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) 
and also includes the Agency for Healthcare Research and Quality (AHRQ), the Centers for 
Medicare and Medicaid Services (CMS), the Department of Agriculture (USDA), the 
Department of Defense (DoD), the Department of Veterans Affairs (VA), the Environmental 
Protection Agency (EPA), the Health Resources and Services Administration (HRSA), the 
Department of Health and Human Services Office of the Assistant Secretary for Preparedness 
and Response (HHS/ASPR), and the Office of the Assistant Secretary for Health (HHS/OASH).
In 2001, the Task Force developed an initial Action Plan, outlining specific issues, goals, and 
actions important for addressing the problem of AR. This document, entitled A Public H ealth  
Action Plan to Com bat Antim icrobial R esistance, P art I: Dom estic Issues, reflected a broad- 
based consensus of participating federal agencies, which was reached with individual input from 
state and local health agencies, universities, professional societies, pharmaceutical companies, 
healthcare delivery organizations, agricultural producers, consumer groups, and other members 
of the public. Continued collaboration with these partners has been vital to achieving successful 
implementation of the Action Plan.
In 2011, the Action Plan was revised based in part on individual input obtained at a consultants’ 
meeting held in Atlanta, Georgia in December 2007. Present at the public meeting were 
consultants with wide-ranging expertise in areas such as human and veterinary medicine, 
pharmaceutical and diagnostics manufacturing, animal husbandry, clinical microbiology, 
epidemiology, and infectious diseases and infection control, and state and local public health 
officials.
This 2012 update reflects changes since the 2011 Action Plan. The Action Plan includes action 
items organized into four focus areas: Surveillance, Prevention and Control, Research, and 
Product Development. Within each of these four areas, specific goals are listed. The focus areas 
and goals are as follows:
I. Surveillance
• Goal 1: Improve the detection, monitoring, and characterization of drug-resistant infections in 
humans and animals.
a In this document, the term “antimicrobial” is used inclusively to refer to any agent (including an antibiotic) used to 
kill or inhibit the growth of microorganisms (bacteria, viruses, fungi, or parasites). This term generally applies to 
agents intended for healthcare, veterinary, and agricultural applications.
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• Goal 2: Better define, characterize, and measure the impact of antimicrobial drug use in 
humans and animals in the United States.
II. Prevention and Control
• Goal 3: Develop, implement, and evaluate strategies to prevent the emergence, transmission, 
and persistence of drug-resistant microorganisms.
• Goal 4: Develop, implement, and evaluate strategies to improve appropriate antimicrobial use.
III. Research
• Goal 5: Facilitate basic research on antimicrobial resistance.
• Goal 6: Facilitate the translation of basic research findings into practical applications for the 
prevention, diagnosis, and treatment of resistant infections.
• Goal 7: Facilitate clinical research to improve the treatment and prevention of antimicrobial 
drug resistant infections.
• Goal 8: Conduct and support epidemiological studies to identify key drivers of the emergence 
and spread of AR in various populations.
IV. Product Development
• Goal 9: Provide information on the status of antibacterial drug product development and 
clarify recommended clinical trial designs for antibacterial products.
• Goal 10: Consider opportunities for international harmonization and means to update 
susceptibility testing information for human and animal use.
• Goal 11: Encourage development of rapid diagnostic tests and vaccines.
The Task Force will continue to facilitate coordination among agencies and monitor
implementation of the plan. As has been done since 2001, the Task Force will continue to
publish annual reports detailing how the plan is being implemented, solicit comments from the
public, and update the plan.
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Introduction and Overview
Background
In the 1940s, the widespread availability of penicillin and the subsequent discovery of 
streptomycin led to a dramatic reduction in illness and death from infectious diseases. However, 
bacteria and other disease-causing organisms — viruses, fungi, and parasites — have a 
remarkable ability to mutate and acquire resistance genes from other organisms and thereby 
develop resistance to antimicrobial drugs. When an antimicrobial drug is used, the selective 
pressure exerted by the drug favors the growth of organisms that are resistant to the drug's action. 
The extensive use of antimicrobial drugs has resulted in drug resistance that threatens to reverse 
the medical advances of the last seventy years.
Drug-resistant pathogens are a growing menace to all people, regardless of age, gender, or 
socioeconomic background. They endanger people in affluent, industrial societies like the United 
States, as well as in less-developed nations. Examples of clinically important microbes that are 
rapidly developing resistance to available antimicrobials include bacteria that cause pneumonia, 
ear infections, and meningitis (e.g., Streptococcus pneum oniae), skin, bone, lung, and 
bloodstream infections (e.g., Staphylococcus aureus), urinary tract infections (e.g., Escherichia  
coli), foodborne infections (e.g., Salmonella or E. coli acquired from meat, eggs, nuts, fresh 
produce etc.), and infections transmitted in healthcare settings (e.g., enterococci, Acinetobacter  
baumanii, Pseudom onas aeruginosa, and K lebsiella  spp.).
Antimicrobial resistance (AR) is not a new phenomenon; however, the current magnitude of the 
problem and the speed with which new resistance phenotypes have emerged elevates the public 
health significance of this issue. In addition, the declining number of new antimicrobial agents 
limits treatment options, particularly for patients with infections caused by multidrug-resistant 
organisms. For example, surveillance data for S. pneum oniae, a common cause of bacterial 
respiratory tract infections, showed that 24 percent of isolates were not susceptible to penicillin. 
In addition, resistance to several other antibacterial drugs is common; 1.5 percent of isolates 
were resistant to cefotaxime (a "third-generation" cephalosporin antibiotic), and resistance to the 
newer fluoroquinolone antimicrobials has already been reported.b Nearly all strains of 
Staphylococcus aureus in the United States are resistant to penicillin, and many are resistant to 
newer methicillin-related drugs. Vancomycin for many years has been the only uniformly 
effective treatment against these methicillin-resistant strains, but over the last decade there have 
been reported strains of S. aureus with decreased susceptibility and isolates resistant to 
vancomycin. The public health burden of methicillin-resistant Staphylococcus aureus (MRSA) is 
staggering, with over 90,000 invasive MRSA infections per year estimated in the U.S. 
population.c
b Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus 
pneumoniae, 2008 available at: http://www.cdc.gov/abcs/reports-findings/survreports/spneu08.pdf 
c Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes 
JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance 
(ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. 
JAMA. 2007 Oct 17;298(15):1763-71.
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Many other pathogens -  including the bacteria that cause tuberculosis and gonorrhea, human 
immunodeficiency virus (HIV), the fungi that cause yeast infections, and the parasites that cause 
malaria -  are also becoming resistant to current therapies. For instance, CDC modified its 
treatment recommendations for gonorrhea in 2007 due to increasing and widespread 
fluoroquinolone resistance in N eisseria gonorrhoeae .d Since 2007, the emergence of N. 
gonorrhoeae with increasing MICs of cephalosporins has the potential to make some cases of 
disease untreatable.e The unpredictable and fluid nature of AR is also illustrated by the 
prevalence of resistant A cinetobacter baumannii among military personnel in and returning from 
conflict areas and in hospital outbreaks in civilian U.S. hospitals. Drug choices for the treatment 
of other infections are becoming increasingly limited and expensive, and, in some cases, 
nonexistent.
Since their discovery, antimicrobials have been used extensively in livestock and poultry for the 
treatment, control, and/or prevention of animal diseases, as well as for production purposes (e.g., 
to enhance growth, improve feed efficiency). In contrast to human medicine where treatment is 
customarily directed at the patient, entire groups of animals may be treated by the use of 
medicated feed and/or water. As a result of continued exposure to antimicrobials, the prevalence 
of resistant bacteria in the fecal flora of food animals can be relatively high. The impact of 
increases in resistant bacteria in food animals on the management of human infections is an 
ongoing concern as many classes of antimicrobials used in food-producing animals have 
analogues to human therapeutics and are therefore capable of selecting for similar resistance 
phenotypes.
Risk
Drug-resistant infections may be acquired in healthcare settings (e.g., gram-negative infections in 
intensive care units), in the community (e.g., pneumococci acquired from a classmate), and 
through the food supply (e.g., salmonella acquired from meat or eggs), both domestically and 
around the world. While anyone may acquire a drug-resistant infection, certain people are at 
increased risk, e.g., patients in hospitals and children in daycare centers. However, resistant
d Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer 
Recommended for Treatment of Gonococcal Infections. MMWR 56(14);332-336. April 13, 2007. 
e Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med. 
2012 Feb 9;366(6):485-7.
f Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S, Lindler L, Mancuso 
J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G, Petersen K, Endy T, 
Petruccelli B.An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the 
U.S. military health care system associated with military operations in Iraq. Clin Infect Dis. 2007 Jun 
15;44(12):1577-84. Epub 2007 May 8.
Jones A, Morgan D, Walsh A, Turton J, Livermore D, Pitt T, Green A, Gill M, Mortiboy D. Importation of 
multidrug-resistant Acinetobacter spp infections with casualties from Iraq. Lancet Infect Dis. 2006 Jun;6(6):317-8. 
Moran KA, McAllister CK, Gray PJ Multidrug-resistant Acinetobacter extremity infections in soldiers. Davis KA,. 
Emerg Infect Dis. 2005 Aug;11(8):1218-24.
Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008 Mar 20;358(12):1271-81.
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microbes are increasingly appearing in new settings. MRSA, which for 30 years was almost 
exclusively a problem in hospitals, is now occurring in the community among otherwise healthy 
persons.g
Costs
The costs of treating AR infections place a significant burden on society — a burden that is 
likely to grow larger as the number of cases of drug-resistant illness increases. Individuals 
infected with drug-resistant organisms are more likely to remain in the hospital for a longer time, 
and to have poorer prognoses.h In a 2008 study of antimicrobial resistant infections acquired in 
the hospital, the medical costs attributable to the infection ranged from $18,588 to $29,069 per 
patient, hospital stays were extended between 6.4 to 12.7 days, and the attributable mortality of 
the resistant infection was 6.5%. Using the most conservative estimates, the total cost of resistant 
infections in the 188 patients from this study was $13.35 million dollars. These findings suggest 
that significant health and economic benefits are possible through efforts to reduce antimicrobial 
resistance and healthcare-associated infections.
Solutions
AR will always be with us. The challenge before us is to transform this increasingly urgent threat 
into a manageable problem. In the past, the Institute of Medicine, the American Society for 
Microbiology, the World Health Organization (WHO), the Congressional Office of Technology 
Assessment, the Government Accountability Office, the Infectious Disease Society of America, 
and other panels of distinguished experts have provided recommendations and options for 
government action to address the dangers posed by AR. In addition, a 2009 U.S.-EU Summit 
Declaration included a statement to establish a transatlantic task force on AR.i The experts agree 
that we need to improve surveillance for emerging AR problems, to prolong the useful life of 
antimicrobial drugs, to develop new drugs, and to utilize other measures (e.g., improved 
vaccines, diagnostics, and infection control interventions) to prevent and control AR.
The problem is urgent, the achievement of these goals has not been simple or straightforward, 
and accomplishments to date, while notable, have been insufficient. Monitoring, preventing, and 
controlling AR requires sustained effort, commitment, and collaboration among many groups in 
the public and private sectors, and involvement of the general public. It also requires continuing 
support and leadership from Federal and state governments and a willingness to address complex 
and sometimes controversial scientific, medical, and economic issues.
Focus Areas
g Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes 
JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance 
(ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. 
JAMA. 2007 Oct 17;298(15):1763-71.
h Roberts, RR, Hota B, Ahmad I, Scott RD II, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, 
Supino M, Naples J, Cordell R, Levy SB, Weinstein, RA. Hospital and societal costs of antimicrobial-resistant 
infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 2009; 49:1175­
84.
i http://www.whitehouse.gov/the-press-office/us-eu-joint-declaration-and-annexes
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The Action Plan includes action items organized into four focus areas: Surveillance, Prevention 
and Control, Research, and Product Development. Each focus area contains specific action items, 
projects and implementation steps. In addition to these, a selection of AR activities, in which the 
Task Force is actively engaging, is highlighted below.j
I. Surveillance
Unless AR problems are detected as they emerge and actions are taken quickly to contain them, 
the world may soon be faced with previously treatable diseases that have again become 
untreatable, as in the pre-antibiotic era. Early detection of new and emerging resistance, ongoing 
monitoring of resistant infections, and information on antimicrobial use will allow experts to 
quickly interpret trends and identify strategies to prevent or mitigate the development and spread 
of AR.
The Action Plan incorporates several action items aimed at strengthening, expanding, and 
coordinating existing national and international surveillance systems for antimicrobial-resistant 
microorganisms. Additional action items in this area focus on addressing barriers to timely 
dissemination and updating of surveillance data and gathering information on antimicrobial use 
practices.
Over the next few years, CDC will address several action items in this focus area by continuing 
to expand and improve its surveillance systems that collect data on AR. For instance, the 
National Healthcare Safety Network (NHSN) is a surveillance system that provides healthcare 
facilities a way to track, analyze, and interpret data on healthcare-associated infections (HAIs), 
including those caused by antimicrobial-resistant pathogens. NHSN is expanding to improve its 
capacity for collection and analysis of data on multidrug-resistant organisms (MDROs) and 
antimicrobial drug use. In addition to monitoring resistance in healthcare settings, CDC is 
maintaining surveillance activities for pathogens affecting the general population through efforts 
such as the Emerging Infections Program (EIP), a population-based network of CDC and state 
health departments, National Antimicrobial Resistance Monitoring System (NARMS), the 
Gonococcal Isolate Surveillance Project, and the National Tuberculosis Surveillance System. 
Through the EIP program, CDC closely monitors invasive bacterial pathogens through Active 
Bacterial Core surveillance. In partnership, FDA, USDA, and CDC track resistance among 
enteric pathogens through NARMS. On-farm pilot projects were initiated in 2011 to test the 
feasibility of expanding NARMS to include a preharvest component to the sampling design. In 
addition to monitoring resistance among bacterial pathogens, CDC continues to monitor 
resistance among non-bacterial pathogens such as influenza, malaria, and HIV, both domestically 
and internationally.
II. Prevention and Control
J These highlighted activities are provided as illustrative examples and do not represent a comprehensive list.
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The prevention and control of antimicrobial-resistant infections requires measures to prevent the 
transmission of resistant microorganisms and promote the appropriate usek of antimicrobial 
agents. While development of new antimicrobial agents and effective stewardship of existing 
agents are cornerstones of activities to protect the health of the nation in the face of expanding 
AR, successful prevention of resistance occurs by reducing the size of the populations of 
resistant microorganisms in humans, animals, and the environment.
Preventing infections with resistant strains of a microorganism can also be accomplished by 
preventing or eliminating all infections caused by that microorganism. For example, drug- 
resistant malaria is rampant in parts of the world, but malaria was effectively eliminated from the 
United States through mosquito control efforts. Antibiotic resistance in H aem ophilus influenzae 
was the threat that dictated antibiotic choice for virtually all invasive bacterial infections in 
young children in the United States as recently as 15 years ago, but following the introduction of 
H aem ophilus infuenzae serotype b (HIB) vaccines this problem has nearly been eliminated.
Action items in this area address extending the useful life of antimicrobial drugs by encouraging 
appropriate use through educational efforts such as the G et Sm art: Know When Antibiotics Work 
campaigns, preventing infection transmission through improved infection control methods and 
use of vaccines, and preventing and controlling emerging AR problems in agriculture, human, 
and veterinary medicine.
AR prevention and control activities that will be key over the next few years include several 
interagency collaborations focused on controlling and preventing MRSA infectionsl within 
healthcare settings. Based upon the successful prevention initiative involving the VA Pittsburgh 
Healthcare System and CDC demonstrating a reduction of MRSA infections, that initiative was 
expanded into an additional 17 sites within the Veterans Health Administration (VHA). The 
VHA’s MRSA Prevention Initiative is now a nationwide effort to reduce healthcare-associated 
MRSA infection in hospital patients. VHA is also evaluating lessons learned from the MRSA 
Prevention Initiative to explore initiatives directed at other MDROs as well as Clostridium  
difficile.
Also continuing over the next few years is an interagency initiative to identify and help suppress 
the spread of MRSA and other related infections through an ongoing partnership between CDC 
and AHRQ. The two agencies are working together to identify gaps in the prevention, diagnosis, 
and treatment of MRSA and related infections across the healthcare system and to fund research, 
implementation, measurement, and evaluation practices that mitigate healthcare-related 
infections.
k
In this Action Plan, appropriate antimicrobial drug use is defined as use that maximizes therapeutic impact while 
minimizing toxicity and the development of resistance. In practice, this means prescribing antimicrobial therapy 
when and only when beneficial to a patient; targeting therapy to the desired pathogens; and using the appropriate 
agent, dose, and duration.
' Jain, R., S.M. Kralovic, et al. (2011). “Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus 
aureus Infections.” New England Journal of Medicine 364(15): 1419-1430.
- 9 -
Several Task Force member agencies, including AHRQ, CDC, FDA, NIH, CMS, and VA are 
working to implement the HHS Action P lan to P reven t H ealth C are-A ssociated Infections 
(HAI)m, which includes reduction targets for both Clostridium  difficile and MRSA. By working 
to implement the HHS HAI Action Plan these agencies and partners will impact several areas 
and action items covered in this 2012 AR Action Plan.
III. Research
Understanding the fundamental processes involved in AR within microbes and the resulting 
impact on humans, animals, and the environment forms an important basis for influencing and 
changing these processes and outcomes. Basic and clinical research provide the fundamental 
knowledge necessary to develop appropriate responses to the emergence and spread of AR in 
hospitals, communities, farms, and the food supply. Critical activities in this focus area include 
support of basic research to uncover new targets and new antimicrobials, investigations into the 
development of resistance and host-pathogen interactions, optimization of treatment for resistant 
pathogens, and translation of research findings into clinically useful products, such as novel 
approaches to detect, prevent, and treat antimicrobial-resistant infections.
NIH continues to engage in AR research activities that address multiple action items in this focus 
area. In addition to an extensive investigator-initiated grants portfolio, NIH supports the basic 
research activities of the Genomic Sequencing Centers for Infectious Diseases and the 
Bioinformatics Resource Centers for Infectious Diseases. The objective of the sequencing 
centers is to provide rapid and cost-efficient production of high-quality genome sequences of 
microorganisms and invertebrate vectors of infectious diseases and to make the resulting 
genomic data rapidly and readily accessible to the broader scientific community through publicly 
accessible international databases. In addition, the sequencing centers provide comparative 
genomics and genotyping services to examine genetic variation in populations and communities 
of human pathogens and also across the human genome to identify genetic associations with 
observable phenotypes in the pathogen and in the human host. The bioinformatics resource 
centers provide the scientific community free access to resources for the query, analysis, and 
display of such information through user-friendly interfaces.
NIH currently supports clinical trials aimed at identifying ways to reduce the use of licensed 
antibacterials in both community and healthcare settings. These trials focus on areas of greatest 
antimicrobial drug exposure, such as pneumonia, otitis media, skin and soft tissue infection, and 
bacteremia, and employ strategies to reduce use, such as shorter courses of antimicrobial 
treatment; using antimicrobials only where indicated; different dosages/frequencies to achieve 
desirable in vivo efficacy; validation of the key components of multi-drug therapy; and optimal 
use of off-patent antimicrobials to prevent the emergence of resistance.
IV. Product Development
m The HHS Action Plan to Prevent Healthcare-Associated Infections is available on the HHS website at: 
http://www.hhs.gov/ophs/initiatives/hai/infection.html
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There is a critical need for new drugs, vaccines, and diagnostic tests to treat, prevent, and 
diagnose infections, including serious and life-threatening infections caused by drug-resistant 
bacteria. FDA is working on a study to better understand the trends over time in the development 
of new antibacterial drugs, the number of drugs approved, and reasons why development 
programs may not have achieved approval.
The Action Plan incorporates action items that will facilitate the development of vaccines and 
diagnostic tests for pathogens for which AR poses a significant problem for treatment or public 
health.
FDA is working on a number of guidances on approaches to evaluating new antimicrobial 
products. Providing guidance can help by identifying recommended scientific approaches and 
also to identify areas where additional developmental work would be beneficial for the design 
and conduct of studies. Over the last few years, FDA has held several public workshops and/or 
Advisory Committee meetings to discuss clinical trial designs for evaluating antibacterial drugs. 
FDA has also published several guidance documents that describe recommended approaches 
regarding clinical trial designs.n
One particular example of the efforts to date is the work to refine clinical trial designs for 
studying antibacterial drugs for the treatment of hospital-acquired bacterial pneumonia (HABP) 
and ventilator-associated bacterial pneumonia (VABP). As part of these efforts, in 2009, FDA 
co-sponsored a public workshop with the Infectious Diseases Society of America, the American 
College of Chest Physicians, the Society of Critical Care Medicine, and the American Thoracic 
Society regarding scientific issues in clinical trial design for HABP and VABP. This public 
workshop provided information about and gained perspective from health care providers, 
academics, and industry on various aspects of antimicrobial drug development for HABP and 
VABP, including diagnosis, treatment, trial endpoints, and statistical issues in analysis of results 
of trials in HABP and VABP.
In the next few years, FDA will engage in activities to address a number of the action items in 
the Product Development focus area. FDA will be working to provide clarity on recommended 
approaches for evaluating new medical products for bacterial disease through publishing 
guidance documents. FDA plans to publish guidance documents on recommended clinical trial 
designs for evaluating antibacterial drugs for conditions such as acute bacterial skin and skin 
structure infections and hospital-acquired and ventilator-associated bacterial pneumonia. In 
addition, FDA also plans to publish guidance for establishing performance for in vitro 
diagnostics assays for MRSA and vancomycin-resistant enterococci (VRE). These guidances 
will describe recommended approaches for developing new antimicrobial products for specific 
uses.
nExamples of recent guidance documents: Antibacterial Drug Products: Use of Noninferiority Studies to Support 
Approval (draft, October 2007), Acute Bacterial Sinusitis: Developing Antimicrobial Drugs for Treatment (draft, 
October 2007), Acute Bacterial Otitis Media: Developing Drugs for Treatment (draft, January 2008), Acute 
Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing 
Antimicrobial Drugs for Treatment (draft, August 2008), Community-Acquired Bacterial Pneumonia: Developing 
Drugs for Treatment (draft, March 2009), Non-Inferiority Clinical Trials (draft, March 2010)
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The Biomedical Advanced Research Development Authority (BARDA), in the HHS Office of 
the Assistant Secretary for Preparedness and Responseo is designing and implementing programs 
that create partnerships between government and industry based on support and incentives that 
induce commercial enterprises to address public health and biodefense priorities.
BARDA is currently supporting the development of an intravenous formulation of a next- 
generation aminoglycoside antibiotic for the treatment of plague and tularemia, as well as 
ventilator-associated pneumonia. In 2012, BARDA established an additional partnership for the 
development of a next generation tetracycline antibiotic for the treatment of anthrax, plague, and 
tularemia, as well as community-acquired bacterial pneumonia. BARDA is projecting an 
expansion of this program in the near-term by supporting the development of more novel 
antimicrobial candidates for the treatment and prevention of diseases caused by bacterial threat 
agents as well as diseases caused by clinically prevalent infectious diseases, including those that 
are antimicrobial resistant.
o See http://www.phe.gov/about/barda/Pages/default.aspx for more information on BARDA
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The Focus Areas
Following each of the goals listed for each focus area are several action items that define topic 
areas for specific projects or implementation steps (numbered items). Wherever possible, action 
items are populated with specific projects or implementation steps (lettered items) to provide 
greater specificity for planned federal activities. The action items, projects, and implementation 
steps do not represent an exhaustive list of activities.p The expected completion dates for specific 
projects and implementation steps are indicated with a date. For example, (2012) means that the 
work is expected to be completed by the end of the 2012 calendar year. Some activities are 
ongoing and are indicated as such. Project lists will be updated annually, and actions will be 
updated every two years.
Focus Area I: Surveillance
Overarching goals
In order to develop and implement effective control strategies there must be 1) continuous or 
periodic monitoring of infections caused by AR microorganisms and 2) comprehensive 
knowledge of the use of antimicrobial agents across all sectors.
Goal 1: Improve the detection, monitoring, and characterization of drug-resistant infections in 
humans and animals.
1.1 Develop strategies to more accurately assess the burden of antimicrobial drug resistance 
in the community through the enhancement of existing systems including the Emerging 
Infections Program (EIP) and the Epidemiology and Laboratory Capacity (ELC) sites.
a) Completed: See Appendix A.
b) Facilitate surveillance for resistant enteric bacteria by construction of a web interface for 
data entry and reporting results between state and federal participants in the National 
Antimicrobial Resistance Monitoring System (NARMS) (2012).
c) Implement electronic tools to query resistance prevalence among enteric pathogens 
collected in NARMS (2015).
d) Report regular summaries of antimicrobial resistance trends and mechanisms among 
foodborne bacterial pathogens on the NARMS website and in the literature (ongoing).
e) Expand the Gonococcal Isolate Surveillance Project (GISP) to include a state public 
health laboratory for sentinel site reference susceptibility testing (2011) and initiate CDC-
p Because of the rapidly evolving nature of AR, there will likely be new or emerging challenges in antimicrobial 
resistance subsequent to the publication of this Action Plan. The Task Force is committed to identifying and 
responding to these issues as they arise.
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administered external quality assessment testing to ensure accurate testing at all 5 sentinel 
sites (2012).
f) Expand GISP to include surveillance to identify the emergence of cephalosporin-resistant 
N eisseria gonorrheae by monitoring for gonorrhea cephalosporin treatment failures
(2011). Data analysis and report will be completed in 2014.
g) NEW: The U.S. Army's Multidrug-resistant organism Repository and Surveillance 
Network (MRSN) at the Walter Reed Army Institute of Research in Silver Spring, MD 
will enhance efforts to extend its surveillance network to monitor the DoD beneficiary 
community worldwide (ongoing).
h) NEW: Conduct and report results of susceptibility testing of representative bacterial 
isolates from enteric disease outbreaks (ongoing).
i) NEW: Link data in NARMS to data in other enteric disease surveillance systems to better 
understand and characterize the burden of resistant enteric infections and to identify risk 
factors for acquiring these infections (ongoing).
j) NEW: Determine food, water, and other sources for resistant versus susceptible enteric 
infections (ongoing).
k) NEW: Identify sources of resistant enteric infections among travelers returning to the 
United States (ongoing).
l) NEW: Determine the prevalence of antimicrobial resistance among enteric organisms of 
livestock on farms (ongoing).
Coordinator: CDC; Collaborators: FDA, USDA, VA, D oD
1.2 Develop strategies to more accurately assess the burden of antimicrobial resistance in 
healthcare settings through the enhancement of existing systems including NHSN, the 
EIP, and ELC sites.
a) Expand NHSN to use electronically-captured antimicrobial susceptibility data from 
participating facilities for reporting of resistance rates and trends; pilot expansion plan in 
2011-2012, provide results of pilot in 2012, develop a web-based query for users in 2014, 
and provide ongoing periodic reports of the collected resistance data.
b) Report regular summaries to provide national estimates of the resistance burden using 
data reported on HAIs to NHSN (ongoing).
c) Evaluate the utility of electronic rules for identifying and reporting central line-associated 
bloodstream infections, surgical site infections (2011), catheter-related urinary tract 
infections (2012), and ventilator-associated pneumonia (2012), including associated
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pathogens; and compare electronic algorithms with traditional manual surveillance by 
infection control professionals (CLABSIs 2011).
d) Develop a system to collect representative sets of bacterial isolates to assess changes in 
resistance mechanisms or strains nationally and work with the Clinical and Laboratory 
Standards Institute (CLSI) to determine the impact of changes on antimicrobial 
susceptibility testing and reporting practices in the United States.
e) Collect convenience samples of bacterial and fungal isolates through the EIP to assess 
changes in antimicrobial-resistant pathogens such as MRSA (ongoing), Clostridium  
difficile (ongoing), and selected gram-negative bacteria (ongoing), as well as community- 
associated pathogens such as S. pneum oniae, N. meningitidis, and Salmonella spp.; 
determine the feasibility of routine isolate submission for validation of antimicrobial 
susceptibility data submitted to NHSN (ongoing).
f) Implement (2011) and analyze (ongoing) a periodic national prevalence survey for 
healthcare-associated infections, including those caused by antimicrobial-resistant 
pathogens.
g) NEW: The U.S. Army's Multidrug-resistant organism Repository and Surveillance 
Network (MRSN) at the Walter Reed Army Institute of Research in Silver Spring, MD 
will assess existing and new PCR and other technologies to more accurately monitor the 
burden of antimicrobial resistance in the global Military Health System and support 
infection control programs (2012).
h) NEW: Develop analytic tools in NHSN for State Department of Health (and any group 
user) to evaluate summary resistance of reported HAIs by group (i.e., state) allowing 
regional and state-level comparisons of HAI-related summary data (2013); report on 
geographic variability in resistance rates among HAIs in U.S. by 2013.
Coordinator: CDC; Collaborator: VA, D oD
1.3 Assess the presence of antimicrobial-resistant microorganisms, such as MRSA, C.
difficile, and vancomycin-resistant enterococci (VRE), among food animals, retail meats, 
and household environment in the United States. Assessment should include comparison 
of isolates from humans, environment, retail meats, and food animals.
a) Completed: See Appendix A.
b) Completed: See Appendix A.
c) Completed: See Appendix A.
d) Completed: See Appendix A.
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e) NEW: Assess the prevalence of C. difficile in livestock on farms throughout the United 
States (2012).
Coordinator: CDC; Collaborators: FDA, USDA
1.4 Identify patient populations colonized or infected with antimicrobial-resistant pathogens 
which may be important both for transmission of pathogens themselves and the transfer 
of resistance genes (e.g. vancomycin-resistant Staphylococcus aureus). Use this 
information to develop prevention strategies.
a) Identify populations at risk for C. difficile and MRSA infections based on data from 
population-based surveillance systems (2013).
b) Conduct (2012) and analyze (2013) studies of colonization with antimicrobial-resistant S. 
pneum oniae to determine the effects of antimicrobial use and pneumococcal vaccination 
on colonization.
c) NEW: The U.S. Army's Multidrug-resistant organism Repository and Surveillance 
Network (MRSN) at the Walter Reed Army Institute of Research in Silver Spring, MD 
will track the occurrence of multidrug resistant organisms in Military Health System 
(MHS) facilities and assess movement of these organisms in the MHS and interactions 
between these organisms (ongoing).
d) NEW: The U.S. Army's Multidrug-resistant organism Repository and Surveillance 
Network (MRSN) at the Walter Reed Army Institute of Research in Silver Spring, MD 
will conduct surveillance for and assess multidrug resistant organism in military working 
dogs (ongoing).
Coordinator: CDC; Collaborator: NIH, VA, D oD
1.5 Strengthen and expand multi-state, national, and international surveillance systems for 
antimicrobial-resistant microorganisms and ensure adequate sentinel surveillance for the 
emergence and spread of critical resistance phenotypes (e.g., penicillin-resistance in 
Group A Streptococcus, multidrug-resistant and extensively drug-resistant tuberculosis 
[XDR TB], oseltamivir-resistant influenza viruses), and strive for more timely 
dissemination of surveillance data.
a) Increase the number and capacity of public health laboratories that routinely monitor for 
influenza antiviral resistance by developing new assays for rapid testing for antiviral 
resistance (2011) and developing web-based reporting systems (2012).
b) Increase the capacity of state public health laboratories to identify antimicrobial-resistant 
organisms among cases of culture-negative clinical syndromes (e.g., meninigitis, 
empyema) using real-time polymerase chain reaction (PCR) for species-specific genes 
and markers of antimicrobial resistance (2013).
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c) Routinely evaluate and monitor isolates captured through ABCs with unusual resistance 
profiles (e.g., penicillin-resistant Group A or Group B Streptococcus, or vancomycin 
resistance among any of the Streptococcus pathogens) to identify resistance and 
characterize the molecular and genetic mechanisms (ongoing).
d) Completed: See Appendix A.
e) Completed: See Appendix A.
f) Completed: See Appendix A.
g) NEW: Evaluate state-based laboratory surveillance and associated public health response 
for MDROs using established meaningful use criteria for electronic laboratory reporting 
(ELR) in states that have made CREs notifiable; assess considerations for integration 
with NHSN (2015).
Coordinator: CDC; Collaborators: DoD, FDA, USDA, VA
1.6 Work with public health associations, including Association of Public Health
Laboratories (APHL) and Council of State and Territorial Epidemiologists (CSTE), to 
define minimal surveillance activities for AR for local, state, and regional health 
departments. Enhance the accurate detection and identification of AR by clinical and 
public health laboratories.
a) Develop consensus definitions for outbreaks of antimicrobial-resistant pathogens that are 
reportable to health departments to optimize the detection, investigation, and resolution 
of outbreaks (ongoing).
b) Completed: See Appendix A.
c) Implement standard protocols for antimicrobial susceptibility testing through CDC’s ELC 
Program (ongoing).
d) Completed: See Appendix A.
e) Establish a web-based training program, updated annually, on laboratory detection of AR 
(pilot in 2013 and implement in 2014).
f) NEW: In anticipation of the shift to culture-independent testing, catalog and prioritize 
resistance genes and other relevant genetic elements that can help predict clinical 
resistance in particular enteric pathogens and develop sentinel approaches for monitoring 
this resistance in the population (2014).
Coordinator: CD C
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1.7 Promote participation of microbiologists and local, state, and national public health 
workers in the design of systems to collect and disseminate AR data to appropriate end­
users. Identify methods to assist laboratories in summarizing and disseminating AR data 
to appropriate end-users and provide methods for individual laboratories to compare their 
data with data in surrounding regions.
a) Establish state-based surveillance networks utilizing NHSN to aggregate local-level data 
on healthcare-associated infections, multidrug-resistant organisms, and/or C. difficile 
infections for targeted prevention interventions (ongoing).
b) Coordinate the collection of AR data for select veterinary bacterial pathogens by 
partnering with state veterinary diagnostic laboratories (2011).
c) NEW: Assess the feasibility of collecting data on selected animal pathogens through state 
veterinary diagnostic laboratories and other private entities (2012).
Coordinator: CDC; Collaborators: FDA, USDA, VA
1.8 Collaborate with surveillance systems in other parts of the world to build global 
surveillance of AR microorganisms.
a) Establish liaisons with reference laboratories in countries without well-developed 
surveillance systems, both to improve the accuracy of global surveillance for resistance 
and to improve local use of the data (ongoing).
b) Support and assist WHO on matters related to integrated surveillance of AR and 
containment of food-related AR through participation in the newly establish WHO 
Advisory Group on Integrated Surveillance of Antimicrobial Resistance (WHO- 
AGISAR) (ongoing).
• NARMS scientists from FDA, CDC, and USDA will provide expert advice to the 
WHO-AGISAR steering committee through participation and information sharing 
(2012).
• Support laboratory capacity building activities in WHO member countries for AR 
monitoring by developing AR modules for Global Foodborne Infections Network 
training courses (2011-2012).
c) Develop collaborations with International Emerging Infections Program (IEIP) sites to 
improve surveillance systems for AR, facilitate prevention programs, and ensure 
appropriate responses to outbreaks of resistant organisms (ongoing).
d) Collaborate with IEIP sites to expand surveillance systems (2011) to measure the burden 
of AR and the impact of infection control interventions in healthcare settings and conduct 
carriage studies (2014) in the community setting.
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Coordinator: CDC; Collaborators: DoD, FDA, USDA
1.9 Develop national and international surveillance systems to monitor understudied areas, 
such as resistance in protozoan parasites (e.g. Plasm odium  spp.), helminthes or 
understudied sexually transmitted diseases (e.g., T. pallidum , T. vaginalis, H erpes  
sim plex), neglected tropical diseases, and resistance to disinfectants, sanitizers, and 
insecticides.
a) Identify resistance mechanisms in Trichomonas and use this information to develop 
laboratory tests for detection of resistance (2012).
b) Identify and characterize markers of artemisinin-based combination therapies (ACT) 
resistance in malaria for the purpose of developing new laboratory tests for surveillance 
(2012).
c) Work with international partners to conduct in vivo / in vitro  studies to monitor the 
efficacy of anti-parasitic drugs (2013).
d) Collect a repository of specimens with characterized antimalarial drug sensitivity patterns 
for the development of laboratory test development and quality control (2012).
Laboratory tests will be used to expand surveillance.
e) Work with international partners to improve laboratory capacity in endemic countries for 
the detection and surveillance of malaria drug-resistant parasites (2012).
f) Evaluate current strategies for deploying insecticides for public health that reduce or 
minimize resistance, and, as necessary, develop new strategies (2012).
g) NEW: Conduct studies to assess the efficacy o f transmission blocking interventions to 
reduce spread of resistant P. falciparum  strains (2012-2014).
h) NEW: Work with host nationals to identify asymptomatic carriers o f drug resistant P. 
falciparum  via active case detection (ongoing).
Coordinator: CDC; Collaborator: D oD
1.10 Assess the risk of AR emergence and spread in food borne pathogens due to 
environmental contamination by antimicrobial drug residues and pesticides in 
collaboration with the existing Pharmaceuticals in the Environment Subcommittee o f the 
Office of Science and Technology Policy.
Coordinator: FDA; Collaborator: EPA
Goal 2: Better define, characterize, and measure the impact o f antimicrobial use in humans and 
animals in the United States.
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2.1 Identify sources of antimicrobial use information in the United States for humans, 
animals, agriculture, aquaculture, and other sectors to establish baseline data on 
antimicrobial use. Develop a standard for collecting and reporting schemes for 
antimicrobial use data that allow aggregation, reporting, and comparisons of trends across 
sectors.
a) Gain access to and summarize de-identified data on antimicrobial use from market 
research companies, health maintenance organizations, federal healthcare systems, and 
other medical care systems in the United States to aid in quantifying antimicrobial use in 
humans and understanding geographical heterogeneity in antimicrobial use (ongoing).
b) Perform a national antibiotic use point-prevalence survey. Pilot survey to be completed 
by 2010 and full survey by 2012.
c) Revise the Antibiotic Use and Resistance module of NHSN to accept electronic data on 
antibiotic use from healthcare facilities by 2011 and begin receiving data by 2012.
d) Completed: See Appendix A.
e) Completed: See Appendix A.
f) NEW: Pilot (2012) and implement (2013-2014) national prevalence survey of appropriate 
antimicrobial use utilizing tools developed in 4.1a, and utilize infrastructure in 2.1b.
g) NEW: Conduct national studies to determine antimicrobial use practices in livestock and 
poultry populations throughout the United States through the USDA:APHIS National 
Animal Health Monitoring System (ongoing).
Coordinator: FDA, CDC; Collaborators: USDA, VA
2.2 Develop mathematical models to guide studies of use and resistance in both humans and 
animals by collating existing data on correlations between antimicrobial use and 
antimicrobial resistance from studies in veterinary and human healthcare settings (e.g., 
cephalosporin use and prevalence of vancomycin-resistant enterococci in intensive care 
units) and community settings (e.g., fluoroquinolone use for respiratory tract infections 
and macrolide resistance in pneumococci).
a) Completed: See Appendix A.
b) NEW: Explore metagenomic approaches to understand ecology of resistance 
determinants in enteric organisms (2015).
c) NEW: Compare the relationship between antibiotic prescribing and C. difficile disease 
rates (2013).
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d) NEW: Compare the relationship between antibiotic use and invasive S . pneum onia  in the 
era of expanded-valent pneumococcal conjugate vaccines (2013).
Coordinator: CDC; Collaborators: USDA, VA
2.3 Implement systems to detect the development and spread of resistance in microorganisms 
during implementation of new programs that significantly impact antimicrobial drug use 
(e.g., pay-for-performance mandates on antibiotic timing for community-acquired 
pneumonia, guidelines for intrapartum prophylaxis to prevent neonatal group B 
streptococcocal disease, mass population-based treatment campaigns for trachoma or 
helminthic infections, or large studies of treating partners or contacts).
a) Monitor the use of intrapartum antimicrobial prophylaxis for the prevention of neonatal 
group B streptococcal infections and the potential impact of prophylaxis on resistant 
cases of neonatal sepsis (2013).
Coordinator: CD C
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Focus Area II: Prevention and Control
Overarching goals
Federal agencies are strong advocates of prevention and control measures that will both decrease 
the development of new resistant microorganisms and stop the transmission of existing resistant 
microorganisms in healthcare institutions, communities, and agriculture.
Goal 3. Develop, implement, and evaluate strategies to prevent the emergence, transmission, and 
persistence of drug-resistant microorganisms.
3.1 Implement and evaluate the impact of community-based interventions, such as 
vaccination campaigns and the promotion of appropriate antibiotic use to reduce the 
spread of AR microorganisms, rates of disease, and antimicrobial use, and to improve 
patient outcomes.
a) Estimate the effectiveness of pneumococcal and influenza vaccines on drug-resistant 
infections caused by those pathogens (2013).
b) Completed: See Appendix A.
c) NEW: Evaluate the impact of electronic clinical decision support on prescribing practices 
in ambulatory care settings (2014).
d) NEW: Provide support to state health departments to implement appropriate antibiotic 
use campaigns and interventions and evaluate their impact (ongoing).
e) NEW: Coordinate the annual health observance Get Smart About Antibiotics Week in 
collaboration with state and local health departments, international health agencies, 
professional organizations, and private corporations to increase awareness about 
antibiotic resistance and improve antibiotic use (ongoing).
Coordinator: CDC; Collaborators, DoD, VA
3.2 Promote use of appropriate interventions, including checklists, to reduce the risk of 
infection associated with catheters and other devices and procedures in healthcare 
settings.
a) Facilitate multicenter prevention collaborative focused on device and procedure-related 
infections in at least 20 states by 2012.
b) Completed: See Appendix A.
c) Completed: See Appendix A.
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d) Completed: See Appendix A.
e) Completed: See Appendix A.
Coordinator: CDC; Collaborators: AHRQ, VA
3.3 Identify and promote successful AR prevention and control programs in healthcare 
settings that utilize existing recommendations for preventing transmission of AR 
organisms.
a) Establish state-based MDRO and C. difficile prevention collaborative in at least 10 states 
by 2011 and evaluate impact by 2013.
b) Completed: See Appendix A.
c) Completed: See Appendix A.
d) Completed: See Appendix A.
Coordinator: CDC; Collaborators: AHRQ, VA, CMS
3.4 Evaluate the effectiveness of infection-control practices, products, and devices in 
healthcare facilities, including long-term healthcare and outpatient settings.
a) Completed: See Appendix A.
b) Initiate studies (2011), collect and process samples (2012), and analyze data (2013) to 
establish standardized methods and baseline levels of contamination of healthcare 
environmental surfaces. These standardized methods and baselines will be used by 
industry and other partners to evaluate the dynamics of contamination and in 
demonstrating the ability of cleaning and disinfection methods to reduce transmission of 
AR pathogens.
c) Evaluate the impact of state-based CDC-funded HAI prevention collaboratives by 2013.
d) Quantify the national impact of HAI prevention efforts by publishing annual national 
summary statistics (standardized infection ratio) of HAI data reported to CDC’s NHSN 
(ongoing).
Coordinator: CDC; Collaborators: AHRQ, DoD, VA
3.5 Identify factors that reduce transmission of drug-resistant pathogens, including infection 
control, in veterinary, agriculture and aquaculture settings (ongoing).
a) Identify critical control points on-farm for dairy production that will decrease
antimicrobial resistant salmonellae (2011). Evaluate interventions in dairy production that 
will decrease antimicrobial resistant salmonellae (2012).
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b) Make available grant funds of up to $4 million through USDA’s National Integrated 
Food Safety Initiative to support systematic studies that identify intervention strategies 
for effective mitigation of AR throughout the food chain. These 4-year grants began in 
2010 and will be completed no later than 2015.
c) Completed: See Appendix A.
d) NEW: A systems approach will be employed to understand and characterize the host- 
pathogen interactions that are manipulated in food animals using novel therapeutic 
approaches with BT peptides (immunomodulators) and CpG oligonucleotides without 
engendering antimicrobial resistance (2013-2015).
e) NEW: ARS researchers at College Station, TX, showed that day-old birds of an 
immunologically efficient genetic line of chickens were much more resistant to 
colonization by Salmonella enteritidis than were birds of a less immunologically efficient 
line. These researchers demonstrated that certain enzymes in the birds (protein kinases) 
and the relevant signaling pathways did in fact contribute to the pathogen resistance 
patterns exhibited in the different bird lines. The work is important because it has 
identified key regulatory points that can be targeted in genetic selection for pathogen- 
resistant and possibly even pathogen-immune commercial poultry (2015).
f) NEW: ARS researchers in Ames, IA, have identified a gene (poxA) in Salmonella 
typhimurium  that, when mutated, dramatically reduces the ability of the bacterium to 
survive numerous stress conditions as well as antibiotic and chemical exposures. 
Furthermore, the gene mutation decreased the ability of S. typhimurium  to colonize the 
pig. As this genetic system is critical for the ability of the salmonellae to cause disease 
and resist antibiotics, it offers a novel target mechanism for intervention development 
against salmonellae (possible vaccine) (2013).
g) NEW: Conduct workshop to solicit input from stakeholders on insights into the issues 
and information gaps that exist in the areas of antimicrobial use and resistance 
monitoring, practices to support judicious antimicrobial use, alternatives to antibiotics, 
and the discovery of new antimicrobials (2012).
Coordinators: FDA, USDA
3.6 Promote research and development of processing technologies to minimize microbial 
contamination of food.
a) Develop alternatives to current antimicrobial treatments and sanitizers for processing 
poultry carcasses (e.g. natural Generally Recognized as Safe [GRAS] products) (2011). 
Evaluate alternative sanitizers for poultry processing and their reduction of food 
pathogens (2012).
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b) Develop alternatives to current processing treatments for the reduction of E. coli in beef
(2011). Evaluate effectiveness of processing treatments (2012).
c) Identify processing interventions to decrease antimicrobial-resistant microorganisms in 
eggs (2011). Evaluate alternative interventions in egg processing for reduction of 
antimicrobial-resistant microorganism (2012).
Coordinator: USDA
3.7 Expand public health education campaigns targeting food producers, food handlers, and 
the general public about food safety practices that reduce microbial contamination of 
food.
a) Completed: See Appendix A.
b) Completed: See Appendix A.
c) Completed: See Appendix A.
d) NEW: Launched the Food Safety Families Campaign (developed by USDA, FDA, CDC, 
and the Ad Council) in English and Spanish, to target parents and caregivers of young 
children (2011). The launch news release reached over 26 million people while broadcast 
coverage reached 13 million. In FY 2012, a Thanksgiving media tour with the Under 
Secretary for Food Safety generated more than 190 TV and radio segments nationwide, 
reaching 20.3 million people. Continue to expand campaign outreach (2012).
e) NEW: Develop three consumer applications for smartphones to reach consumers with the 
latest, most up-to-date food safety information (2012).
f) NEW: Through the internet and other mechanisms, educate food producers, food 
handlers, and the general public about the major sources and ecology of resistant and 
susceptible bacterial enteric infections in humans (2014).
g) NEW: Educate consumers about food safety through the USDA Food Safety Discovery 
Zone, launched in 2010, which travels throughout the United States visiting community 
events (ongoing).
h) NEW: Conduct food safety education events in Washington D.C. for National Nutrition 
Month (ongoing).
Coordinator: USDA, FDA, CD C
3.8 Promote infection control education at all stages of training and practice for healthcare 
workers in human and veterinary medicine.
a) Completed: See Appendix A.
b) Completed: See Appendix A.
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Coordinator: CDC; Collaborator: USDA, VA
3.9 Develop interagency programs in collaboration with regulators, payers, professional 
societies and other stakeholders to promote effective hand hygiene strategies in 
communities and healthcare settings and to foster the use of biomedical devices and 
behaviors that prevent the transmission of infectious organisms in community settings.
a) Completed: See Appendix A.
b) Completed: See Appendix A.
Coordinator: CDC; Collaborator: AHRQ, VA
Goal 4: Develop, implement, and evaluate strategies to improve appropriate antimicrobial use.
4.1 Identify factors and strategies that promote appropriate antimicrobial use (i.e., best
practices) or discourage inappropriate use in all types of healthcare settings, including 
inpatient and outpatient facilities, clinics and offices. Facilitate the implementation of 
these strategies.
a) Develop algorithms and reporting tools to facilitate local monitoring of antimicrobial use 
(pilot 2011 and implement 2012) and resistance rates (pilot 2011).
b) Completed: See Appendix A.
c) Completed: See Appendix A.
d) Completed: See Appendix A.
e) Examine the impact of improved antimicrobial use on adverse events associated with 
antimicrobials, especially C. difficile infections by 2011. Two manuscripts will be 
developed in 2012.
f) Evaluate the benefits and potential unintended consequences of clinical guidelines and 
policies that bear on antimicrobial use and affect patient care, reimbursement, and other 
areas of medical practice (e.g., increased use of antimicrobial agents in emergency rooms 
for unconfirmed community-acquired pneumonia) (2014).
g) NEW: Explore feasibility of correlating outpatient antimicrobial use with incidence of 
community-based C. difficile infection to inform efforts at reducing infection through 
community-based stewardship (2013).
h) NEW: Examine knowledge, attitudes and behaviors of healthcare providers regarding 
antibiotic choice (2013).
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Coordinator: CDC; Collaborators: AHRQ, FDA, VA
4.2 Promote, implement, and evaluate guidelines for appropriate antimicrobial use in 
agricultural and veterinary settings. Specifically,
a) Seek appropriate expert input to update specific aspects of guidance 152 (particularly the
antimicrobial drug ranking in Appendix A of guidance) and publish revised draft
guidance for public comment (2011-2012).
b) Completed: See Appendix A.
c) Completed: See Appendix A.
d) Survey orchards periodically for emerging resistance among agricultural bacterial plant 
pathogens (e.g., Erwinia am ylovera, Pseudom onas syringae, and Xanthomonas 
cam pestris) to tetracycline, streptomycin, gentamicin, or other antimicrobial agents that 
may be used, such as kasugamycin. Monitoring is conducted to comply with pesticide use 
authorization.
e) NEW: Develop or update educational materials on the judicious use of antimicrobial 
agents in food animals and make those materials available to veterinarians, veterinary 
students, and food animal producers (2014).
f) NEW: Implement and maintain an education module on judicious antimicrobial use for 
veterinarians through the USDA: APHIS National Veterinary Accreditation Program 
(ongoing).
Coordinators: FDA; Collaborators: CDC, USDA, EPA
4.3 Promote the development of improved field-based methods to measure the quality of 
antimalarial drugs, given that poor quality drugs contribute to antimicrobial drug 
resistance.
Coordinator: CD C
4.4 Develop, implement, and evaluate treatment algorithms for management of common 
clinical syndromes frequently treated with antibiotics (e.g., ventilator-associated and 
community-acquired pneumonia, acute bronchitis and sinusitis, and asymptomatic 
bacteriuria and sexually transmitted diseases).
a) Update the Principles o f  Judicious Use o f  A ntim icrobial Agents fo r  P ediatric Upper 
R espiratory Infections and develop and disseminate academic detaining sheet with 
diagnosis and treatment algorithms (2013).
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b) Update the Guidelines fo r  A ppropriate Antibiotic Use fo r  Treatment o f  Acute Respiratory  
Tract Infections in Adults and develop and disseminate academic detailing sheet with 
diagnosis and treatment algorithms (2014).
Coordinator: CDC; Collaborator: NIH, VA
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Focus Area III: Research
Overarching goals
Encourage, conduct, and support basic and translational research to enhance our understanding 
of factors leading to the development of AR microorganisms, their transmission in various 
settings, and optimal modes of prevention, diagnosis, and therapy.
Goal 5: Facilitate basic research on AR.
5.1 Conduct and support genetic, biochemical, and structural studies of AR factors to enable 
the identification of novel drug, diagnostic, and vaccine targets.
Coordinator: NIH
5.2 Investigate naturally occurring mechanisms of resistance, gene transfer, and host- 
pathogen interactions.
Coordinators: CDC, NIH; Collaborators: FDA, USDA
5.3 Investigate the role of biofilms in the development of resistant microorganisms and 
transfer of resistance genes among diverse genera of microorganisms.
Coordinators: CDC, NIH; Collaborators: FDA, USDA
5.4 Develop and make available genomics, metagenomic, bioinformatics, proteomics, 
structural biology, molecular imaging, and other emerging research technologies. Ensure 
that genomic, proteomic, and other related data sets are made publicly available rapidly 
through searchable public online databases and provide data analysis tools to assist 
researchers in using these resources.
Coordinator: NIH; Collaborators: CDC, DoD, FDA, USDA
5.5 Bring new researchers into the field by utilizing appropriate strategies such as training 
and research opportunities.
Coordinators: CDC, NIH; Collaborator: FDA
Goal 6: Facilitate the translation of basic research findings into practical applications for the 
prevention, diagnosis and treatment of resistant infections.
6.1 Facilitate preclinical studies, including toxicology, pharmacokinetics,
pharmacodynamics, and in vitro  and in vivo  activity o f antimicrobial agents to inform the 
treatment o f resistant pathogens.
Coordinator: NIH; Collaborators: CDC, FDA
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6.2 Encourage, support, and conduct basic and clinical research on the development and use 
of vaccines and novel or alternative approaches for prevention and treatment of infections 
in human and veterinary medicine.
Coordinators: NIH, USDA; Collaborators: CDC, DoD, FDA
6.3 Encourage, support, and conduct research on the development of novel diagnostic 
technologies to rapidly distinguish among pathogens and their resistant subtypes at the 
point of care.
Coordinator: NIH
6.4 Support development of novel broad spectrum antimicrobials with dual indications for 
community and hospital acquired infections and biodefense threat agents.
Coordinator: ASPR/BARDA; C ollaborator: NIH, CD C
Goal 7: Facilitate clinical research to improve the treatment and prevention of AR infections.
7.1 Conduct and support clinical research to evaluate the safety and efficacy of novel drugs 
and vaccines for pathogens where resistance threatens effective treatment.
Coordinator: NIH
7.2 Design and implement studies focused on optimizing the dose and duration of 
antibacterial agents prescribed for treatment of community-acquired pneumonia, urinary 
tract infections, skin and soft-tissue infections, and other infectious illnesses.
Coordinator: NIH
Goal 8: Conduct and support epidemiological studies to identify key drivers of the emergence 
and spread of AR in various populations.
8.1 Investigate the interplay among AR, colonization, and disease in acute, long-term care, 
and outpatient facilities.
Coordinator: CDC; Collaborator: NIH, VA
8.2 Support research on how prevalence data on antimicrobial resistance can be used to help 
guide treatment choices. For example, define geographic heterogeneity of resistance rates 
and determine impact of treatment decisions.
a) Define appropriate methods for collection and distribution of information on prevalence 
of resistance to community physicians and veterinarians.
b) NEW: Develop capacity in developing countries to conduct genomic and bioinformatics- 
based molecular epidemiological studies to inform public health drug resistance 
containment and elimination efforts (ongoing).
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Coordinator: CDC; Collaborators: FDA, USDA, VA
8.3 Evaluate the utility of monitoring sentinel human populations (e.g., farm, abattoir, fruit
and vegetable, and food processing plant workers) and persons in the general community 
for infection or colonization with resistant enteric bacteria to identify reservoirs o f 
resistant organisms.
a) Investigate risk factors for AR development in Salmonella and C am pylobacter in food 
animals (2014).
Coordinator: CDC; Collaborator: FDA, USDA
8.4 Develop options to capture and record AR research for all federal agencies. 
Coordinators: CDC, NIH; Collaborators: AHRQ, EPA, FDA, USDA
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Focus Area IV: Product Development
Overarching goals
Encourage the development of new antimicrobial products to improve our capacity to diagnose, 
prevent and treat infections, including infections caused by resistant microorganisms.
Goal 9: Provide information on the status of antibacterial drug product development and clarify 
recommended clinical trial designs for antibacterial products.
9.1 Examine trends over time for new drug applications for systemic antibacterial drugs.
a) Perform pilot phase of study to evaluate trends over time for new drug applications for 
systemic antibacterial drugs; complete assessment of trends over time for new drug 
applications for systemic antibacterial drugs (2011) and publish findings (2012).
Coordinator: FDA
9.2 Publish guidance documents for the following conditions describing recommended 
approaches on clinical trial designs for evaluating antibacterial drugs.
a) Publish guidance on recommended approaches to clinical trial designs for evaluating 
antibacterial drugs for acute bacterial skin and skin structure infections (2012).
b) Publish guidance on recommended approaches to clinical trial designs for evaluating 
antibacterial drugs for hospital-acquired and ventilator-associated bacterial pneumonia
(2012).
c) Publish updated guidance on recommended approaches to clinical trial designs for 
evaluating antibacterial drugs for community-acquired bacterial pneumonia. Publish 
updated draft guidance (2011) and final guidance (2012).
Coordinator: FDA
9.3 Publish guidance documents for the following types of devices to provide 
recommendations regarding product development.
a) Publish final guidance document on premarket notification [510(k)] submissions for 
medical devices that include antimicrobial agents (2012).
b) Publish draft guidance for establishing performance for in vitro  diagnostics assays for 
MRSA and VRE (2011). Publish final guidance (2012).
c) Publish draft guidance document for establishing performance for in vitro diagnostic 
assays for C. difficile. Publish final guidance (2011).
Coordinator: FDA
9.4 Provide regulatory advice on recommended regulatory pathways for evaluating products 
that target unmet medical or veterinary needs including approaches to evaluating non- 
traditional products, e.g., cytokine, probiotics, and antimicrobial peptides (ongoing).
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Coordinator: FDA; Collaborator: USDA
9.5 Evaluate use of the Orphan Drug Act, or similar incentives, to encourage development 
and marketing of new antimicrobial agents for human medicine.
a) Completed: See Appendix A.
Coordinator: FDA
9.6 Sponsor a study to evaluate incentives to promote the development of antibacterial drugs 
for human use and rapid diagnostic tests (including antimicrobial susceptibility tests), 
including the impact of such strategies upon appropriate use of such products. Prepare a 
report for publication describing the study results (2012).
Coordinator: HHS/ASPE
Goal 10: Consider opportunities for international harmonization and means to update 
susceptibility testing information for human and animal use.
10.1 Pursue interagency collaborations to discuss international harmonization of standards and 
regulatory requirements for antimicrobial products (e.g., International Conference on 
Harmonization, International Cooperation on Harmonization of Technical Requirements 
for Registration of Veterinary Medical Products) (ongoing).
Coordinator: FDA
10.2 Collaborate with relevant international organizations and use international expert 
consultations (e.g., the WHO, the World Organization on Animal Health, CLSI standards 
Institute, the European Committee on Antimicrobial Susceptibility Testing) to enhance 
product development (ongoing).
Coordinator: FDA
10.3 Develop a strategy for periodic updating of susceptibility testing information for 
antimicrobial agents approved for use in humans and animals in the United States 
(ongoing).
a) Participate in multi-laboratory method trial studies to develop standardized in vitro
antimicrobial susceptibility testing methods for veterinary pathogens where such tests are 
lacking (2011).
Coordinators: CDC, FDA; Collaborator: USDA
Goal 11: Encourage development of rapid diagnostic tests and vaccines.
11.1 Encourage development, testing, and evaluation of new rapid diagnostic methods for
human and veterinary use to help guide antimicrobial therapy. Specifically, promote the 
development of tests for infections cause by fastidious (e.g. TB) or difficult to culture 
organisms (e.g. Treponema pallidum , the agent of syphilis) and rapid point-of-care
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diagnostics to identify patients with viral respiratory infections who do not need 
antimicrobial agents.
a) Encourage improved diagnostic tests for resistant TB by conducting a FDA/CDC/NIH 
co-sponsored meeting to identify gaps in TB diagnostics and to explore models and 
strategies that may expedite the development of new diagnostics (2010). Work to 
develop, evaluate, and implement molecular tests for the detection of MDR-TB directly 
from pulmonary specimens (2012).
b) Encourage development of rapid point-of-care tests to confirm diagnoses of possible 
bacterial respiratory infections including otitis media, sinusitis, and pneumonia and to 
identify pathogens associated with these infections (ongoing).
c) Completed: See Appendix A.
Coordinators: CDC, FDA; Collaborators: NIH, USDA, VA
11.2 Encourage development, testing, and evaluation of new vaccines for human pathogens 
for which AR poses a significant problem for treatment or public health.
a) Working with stakeholders, examine strategies to maximize the quality and the quantity 
of candidate vaccines for prevention of antimicrobial-resistant infections of public health 
significance (ongoing).
b) Conduct research to facilitate development of vaccines for resistant pathogens such as 
Staphylococcus aureus, M ycobacterium  tuberculosis, C. difficile, enteric pathogens, and 
N eisseria gonorrhoeae (ongoing).
c) Conduct research to facilitate development of vaccines for viral respiratory infections that 
may contribute to increased antibiotic use due to subsequent or co-bacterial infections or 
inappropriate antibiotic use (ongoing).
Coordinator: FDA; Collaborators: CDC, NIH, VA
11.3 Completed: See Appendix A.
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Acronyms and Abbreviations
AHRQ Agency for Healthcare Research and Quality
APHL Association of Public Health Laboratories
AR Antimicrobial resistance
ASH Office of the Assistant Secretary for Health (HHS)
ASPE Office of the Assistant Secretary for Planning and Evaluation
ASPR Office of the Assistant Secretary for Preparedness and Response (HHS)
BARDA Biomedical Advanced Research Development Authority
CDC Centers for Disease Control and Prevention
CLSI Clinical and Laboratory Standards Institute
CMS Centers for Medicare and Medicaid Services
CSTE Council of State and Territorial Epidemiologists
DoD Department of Defense
EPA Environmental Protection Agency
FDA Food and Drug Administration
HAI Healthcare-associated infection
HAP Hospital-acquired pneumonia
HHS Department of Health and Human Services
HRSA Health Resources and Services Administration
IPEC Inpatient Evaluation Center
MDRO Multidrug-resistant organism
MRSA Methicillin-resistant Staphylococcus aureus
NHSN National Healthcare Safety Network
NIH National Institutes of Health
USDA United States Department of Agriculture
VA Department of Veterans Affairs
VAP Ventilator-associated pneumonia
VHA Veterans Health Administration
XDR TB Extensively drug-resistant tuberculosis
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Appendix A: Retired Projects and Implementation Steps
This Appendix lists all projects and implementation steps that the Task Force retired from the 
2012 Action Plan.
Project 
Number 
and Letter
Project Description Reason for 
Retirement
1.1a Implement a multi-site community-onset pneumonia etiology 
study among persons admitted with pneumonia and evaluate 
the specific role of antibacterial and antiviral resistance in 
determining outcomes associated with pneumonia (2011).
Completed 
See 2011 Annual 
Progress Report
1.3a Design and implement a 1 year prevalence study of MRSA, 
VRE, and C. difficile from retail meat (2011).
Completed 
See 2011 Annual 
Progress Report
1.3b Evaluate the quantity of C. difficile recovered from retail 
meats in FoodNet sites.
Completed 
See 2011 Annual 
Progress Report
1.3c Evaluate the quantity of C. difficile recovered from retail 
meats in FoodNet sites.
Completed 
See 2009 -  2010 
Annual Progress 
Report
1.3d Conduct a pilot study to evaluate C. difficile environmental 
contamination in households of infected and non-infected 
patients.
Completed 
See 2011 Annual 
Progress Report
1.5d Assess the impact of including data on susceptibility to 
multiple fluoroquinolones and injectable agents 
(aminoglycosides and capreomycin) to the national TB 
reporting system for enhanced detection of XDR TB.
Completed 
See 2009 -  2010 
Annual Progress 
Report
1.5e Complete a pilot exercise to expand routine nationwide 
surveillance for MDR TB to include additional drugs and 
determine whether this additional surveillance provides useful 
information that warrants broader implementation.
Completed 
See 2009 -  2010 
Annual Progress 
Report
1.5f Organize, plan and conduct a NARMS public scientific 
meeting to highlight results and related AR research and 
solicit input from stakeholders and international partners on 
future enhancements and improvements.
Completed 
See 2011 Annual 
Progress Report
1.6b Disseminate expert recommendations for effective state-based 
surveillance for multidrug-resistant organisms related to 
healthcare-associated infections.
Completed 
See 2011 Annual 
Progress Report
1.6d Develop and implement an antimicrobial susceptibility testing 
training program for public health laboratories (2012).
Completed 
See 2009 -  2010 
Annual Progress 
Report
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2.1d Collect and publish annual reports on animal antimicrobial 
drug distribution data through implementation of Section 105 
of the Animal Drug User Fee Amendments of 2008 (2010 and 
ongoing).
Completed 
See 2011 Annual 
Progress Report
2.1e Collect data through the National Animal Health Monitoring 
System to produce 3 reports on antimicrobial use practices on 
livestock and poultry operations in the United States. These 
reports (shown below) will be produced by July 2011:
• Food Safety Pathogens Isolated from U.S. Dairy 
Operations, 1996-2007
• Antimicrobial Use and Resistance on Beef Cow-calf 
Operations in the U.S. 2007-08
• Antimicrobial Use and Resistance Across Livestock 
and Poultry Operations - A compilation of data from 
the National Animal Health Monitoring System 
studies
Completed 
See 2011 Annual 
Progress Report
2.2a Compare retail pharmacy sales of outpatient oral 
antimicrobials to geographic differences in bacterial 
resistance (2011).
Completed 
See 2011 Annual 
Progress Report
3.1b Evaluate factors that influence the prescribing practices of 
primary care physicians, including academic detailing and 
benchmark analysis (2011).
Completed 
See 2011 Annual 
Progress Report
3.2b Design and implement systems to measure healthcare 
processes that are linked to outcome data in order to measure 
the adherence of healthcare personnel to prevention measures.
Completed 
See 2011 Annual 
Progress Report
3.2c Correlation between adherence to best catheter insertion 
practices and CLABSI rates (2011).
Completed 
See 2011 Annual 
Progress Report
3.2d Revise and publish HICPAC guidance for prevention of 
catheter-associated bloodstream infections.
Completed 
See 2011 Annual 
Progress Report
3.2e Revise and publish HICPAC guidance for prevention of 
surgical site infections (2011).
Completed 
See 2011 Annual 
Progress Report
3.3b Evaluate impact of the CMS-Quality Improvement 
Organization MRSA prevention initiative by 2012.
Completed 
See 2011 Annual 
Progress Report
3.3c Evaluate impact of the Department of Veterans Affairs 
National MRSA prevention initiative (2012). Explore the 
expansion of prevention initiatives to include other MDRO 
including C. difficile and multidrug-resistant gram-negative 
pathogens.
Completed 
See 2011 Annual 
Progress Report
3.3d Facilitate initiation of at least one regional, multi-center 
prevention collaborative in which acute and long-term care
Completed 
See 2011 Annual
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facilities address prevention of multi-drug resistant infections 
in a coordinated manner (2011).
Progress Report
3.4a Expand CDC’s Prevention Epicenter Program to include 
academic centers, integrated health systems, and healthcare 
departments to support early translation of technical advances 
and epidemiologic knowledge into evidence-based 
recommendations (2011).
Completed 
See 2011 Annual 
Progress Report
3.5c Identify factors important for assuring that antimicrobial 
drugs are used judiciously in veterinary, agriculture and 
aquaculture environments.
Completed 
See 2011 Annual 
Progress Report
3.7a Co-host the 2010 Food Safety Education Conference: USDA 
and NSF International will co-host a 3-day conference 
sponsored by HHS, FDA, CDC, and WHO. The conference is 
designed for attendees to share the most current research, 
learn best practices, and explore cutting-edge strategies for 
reducing foodborne illness.
Completed 
See 2009 -  2010 
Annual Progress 
Report
3.7b Launch new USDA Food Safety Mobile Program in spring 
2010 as part of the Food Safety and Inspection Service’s 
ongoing consumer education campaign to reach consumers 
where they live. The USDA Food Safety Mobile will travel 
throughout the United States visiting local community events 
to educate consumers about food safety. The revamped 
program will offer consumers in-depth, interactive, hands-on 
Completed demonstrations on the science of food safety 
based on the four Be Food Safe Campaign messages: Clean, 
Separate, Cook and Chill. The Mobile’s interactive learning 
stations are designed to improve consumer’s food safety 
awareness, knowledge, and behavior.
Completed 
See 2011 Annual 
Progress Report
3.7c Host USDA Nutrition Month to include Food Safety Day on 
March 10, 2010 to increase consumer awareness about food 
safety.
Completed 
See 2011 Annual 
Progress Report
3.8a Complete basic infection control curriculum for posting on 
the CDC website by 2011.
Completed 
See 2009 -  2010 
Annual Progress 
Report
3.8b Develop a plan for infection control education of veterinary 
medicine workers by 2011.
Completed 
See 2009 -  2010 
Annual Progress 
Report
3.9a Develop a plan to collaborate with WHO on their hand 
hygiene promotion campaign.
Completed 
See 2011 Annual 
Progress Report
3.9b In collaboration with academic partners, complete research 
studies that evaluate the impact of novel technologies for 
measuring hand hygiene adherence in the healthcare setting 
(2011).
Completed 
See 2011 Annual 
Progress Report
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4.1b Develop a “change package” for improving antimicrobial use 
in in-patient healthcare settings.
Completed 
See 2011 Annual 
Progress Report
4.1c Collaborate with a network of hospitals to identify patient- 
level indications for and factors associated with antibiotic use 
to help guide efforts on improving use by 2011.
Completed 
See 2011 Annual 
Progress Report
4.1d Examine knowledge, attitudes, and behaviors of healthcare 
providers regarding adverse events and antimicrobial use.
Completed 
See 2011 Annual 
Progress Report
4.2 b Publish and seek public comment on draft guidance outlining 
FDA’s current thinking on the judicious use of medically 
important antimicrobial drugs in food-producing animals.
Completed 
See 2009 -  2010 
Annual Progress 
Report
4.2c Publish a revised order to prohibit certain extralabel uses of 
cephalosporin antimicrobial drugs in food producing animals 
due to AR concerns (2011).
Completed 
See 2011 Annual 
Progress Report
9.5a Part 15 public hearing held April 28, 2008, on issues in AR 
and the Orphan Drug Act.
Completed 
See 2009 -  2010 
Annual Progress 
Report
11.1c Encourage development of rapid point-of-care tests to 
confirm diagnoses of possible bacterial respiratory infections 
including otitis media, sinusitis, and pneumonia and rapid 
point-of-care tests to identify pathogens associated with these 
infections (ongoing).
Completed 
See 2009-2010 
Annual Progress 
Report
11.3 Support advanced development of vaccines for resistant 
pathogens such as Staphylococcus aureus.
Work was not 
initiated and 
determined to be 
beyond the 
current scope of 
work at BARDA
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